BJDX logo

BLUEJAY DIAGNOSTICS INC

BJDXNASDAQ
๐Ÿ† #4151 by market capUS Equity
$1.07โ–ฒ $0.09 (+8.39%)
๐ŸŒ™ After hours$1.03โ–ผ 3.74%Regular close ยท extended-hours price shown
1hโ€”
24hโ–ฒ 8.4%
7dโ€”
14dโ€”
30dโ€”
1yโ€”
๐ŸฆMarket Cap
$1M
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
-100.0%
Declining
๐Ÿ“ŠGross Margin
โ€”
๐Ÿ’ตFCF Margin
โ€”
โš–๏ธP/S Ratio
โ€”
Otter Score
64
Fair
No chart data available for BJDX.

Trading Snapshot

Day Range
$1.06 โ€“ $1.09
52-Week Range
$0.83 โ€“ $16.68
Volume
$3.00B
Avg Volume
$3.84B
Shares Outstanding
1.0M
Next Earnings
Sep 7, 2026

Fundamentals Snapshot

Annual Revenue
$131,202
Last Q Revenue
$34,732
P/E Ratio
โ€”
P/S Ratio
โ€”
EPS (TTM)
$-53.96
Dividend Yield
โ€”

Why Investors Own BJDX

  • โœ“High-growth profile โ€” revenue up +45.1% YoY with expanding US Equity exposure.
  • โœ“Healthy economics โ€” 55% gross margin and 6% free-cash-flow margin.
  • โœ“New products and segments could unlock additional revenue streams.
โš ๏ธ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$131,202โ–ฒ +44.5% YoY
Gross Margin (TTM)
54.9%โ–ผ โˆ’0.3% YoY
Operating Income (TTM)
$17,581โ–ฒ +44.5% YoY
Free Cash Flow (TTM)
$7,872โ–ฒ +44.5% YoY

About BLUEJAY DIAGNOSTICS INC

Bluejay Diagnostics, Inc. functions as a company specializing in medical diagnostic solutions. A key offering is their Symphony platform, an advanced technological system. This platform is composed of the Symphony analyzer, which skillfully orchestrates the processing of whole blood, the isolation of biomarkers, and the preparation of immunoassays using non-contact centrifugal force. It also includes the Symphony Cartridge, which comes pre-loaded with essential reagents and components. The company additionally provides the ALLEREYE diagnostic test, a convenient, on-site device for quickly identifying allergic conjunctivitis. Bluejay Diagnostics is also progressing with the development of Symphony IL-6 tests, intended for monitoring disease advancement in critical care environments. Furthermore, they are actively creating additional diagnostic tests for their Symphony platform, such as those aimed at detecting myocardial infarction (heart attack) and congestive heart failure. Bluejay Diagnostics, Inc. was founded in 2015 and is headquartered in Acton, Massachusetts.

๐Ÿฆฆ

Otter Score Breakdown

โ“˜
๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Fair
64/100

Analyst Ratings

โ“˜
Consensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Jul 2024

Latest News & Updates